Lixte Biotech Hlds (LIXT)

$7.00 +0.29 (4.32%)
Market Cap 83.09M
Revenue (ttm) 0.00
Net Income (ttm) -6.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 183,300
Avg Vol 96,550
Day's Range N/A - N/A
Shares Out 12.38M
Stochastic %K 77%
Beta 1.27
Analysts Strong Buy
Price Target N/A

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab t...

Industry: Biotechnology
Sector: Healthcare
Phone: 631 830 7092
Fax: 631 982 5050
Website: lixte.com
Address:
680 East Colorado Boulevard, Suite 180, Pasadena, United States
DARKP00L
DARKP00L Jun. 3 at 1:09 PM
$LIXT 08:38 on Jun. 03 2026 LIXTE Biotechnology Announces ~$16.57M Registered Direct Offering, Selling ~2.625M Shares And Pre-Funded Warrants At A Combined Price Of $6.31 #tradeideas
0 · Reply
topstockalerts
topstockalerts Jun. 2 at 1:15 AM
$LIXT the buyers seem to be operating with confidence.
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 2:01 PM
$LIXT 08:52 on Jun. 01 2026 LIXTE Biotechnology To Seek Strategic Acquisition Partner For Its Clinical Stage Pharmaceutical And Med-Tech Business #tradeideas
0 · Reply
Scoty_D
Scoty_D Jun. 1 at 1:47 PM
$LIXT The tape is looking funky. 1 share fight going back n forth, odd.
0 · Reply
rockitpicks
rockitpicks Jun. 1 at 1:25 PM
$LIXT There is more going on then what the headline reads..They always release a snippet of info before the full story. This might be building into a serious runner
0 · Reply
Paraboljoker
Paraboljoker Jun. 1 at 12:53 PM
$ADVB $LIXT bio watch lowfloats on 🤔
0 · Reply
TA_Kongen
TA_Kongen Jun. 1 at 12:52 PM
$LIXT LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors Years of biotech headlines all fluff. No real company pivots one day into AI after years of biotech work lmfao.
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 1 at 12:50 PM
$LIXT LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
0 · Reply
DavidScott
DavidScott Jun. 1 at 2:52 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $TROO $LIXT $TOON $NNDM $INO
0 · Reply
focafoca99
focafoca99 May. 14 at 9:28 PM
$LIXT citing its Q1 2026 10‑Q, reported progress on its LB‑100 trial and expansion of its Liora proton‑therapy subsidiary.
0 · Reply
Latest News on LIXT
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

Jun 3, 2026, 8:30 AM EDT - 1 day ago

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

Jun 1, 2026, 8:50 AM EDT - 3 days ago

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

May 14, 2026, 5:18 PM EDT - 21 days ago

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

Lixte Biotechnology presents preliminary LB100 results

2026-04-13T12:06:01.000Z - 7 weeks ago

Lixte Biotechnology presents preliminary LB100 results

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

Apr 13, 2026, 8:00 AM EDT - 7 weeks ago

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

Mar 31, 2026, 3:45 PM EDT - 2 months ago

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

Lixte Biotechnology appoints Sidney Braun as CEO, Liora

2026-02-18T13:20:27.000Z - 3 months ago

Lixte Biotechnology appoints Sidney Braun as CEO, Liora

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

Feb 18, 2026, 8:00 AM EST - 3 months ago

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

Jan 21, 2026, 8:00 AM EST - 4 months ago

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

Jan 20, 2026, 8:00 AM EST - 4 months ago

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

Lixte Biotechnology engages IBN for corporate communications

2026-01-13T13:42:44.000Z - 5 months ago

Lixte Biotechnology engages IBN for corporate communications

Lixte Biotechnology expands collaboration to expand trial with LB-100

2025-12-23T13:20:27.000Z - 5 months ago

Lixte Biotechnology expands collaboration to expand trial with LB-100

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Dec 23, 2025, 8:00 AM EST - 5 months ago

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Lixte Biotechnology prices 1.05 units at $4.09 in registered direct offering

2025-12-18T14:05:36.000Z - 6 months ago

Lixte Biotechnology prices 1.05 units at $4.09 in registered direct offering

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

Dec 8, 2025, 8:30 AM EST - 6 months ago

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

Dec 3, 2025, 11:00 AM EST - 6 months ago

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

Dec 3, 2025, 8:00 AM EST - 6 months ago

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

Lixte Biotechnology acquires Liora’s proton therapy platform

2025-11-25T13:45:50.000Z - 6 months ago

Lixte Biotechnology acquires Liora’s proton therapy platform

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

Nov 25, 2025, 8:30 AM EST - 6 months ago

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Oct 29, 2025, 8:00 AM EDT - 7 months ago

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Lixte Biotechnology outlines its Q4 priorities, provides development updates

2025-10-16T12:11:44.000Z - 8 months ago

Lixte Biotechnology outlines its Q4 priorities, provides development updates

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Oct 16, 2025, 8:00 AM EDT - 8 months ago

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

Sep 16, 2025, 8:30 AM EDT - 9 months ago

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

Sep 15, 2025, 5:40 PM EDT - 9 months ago

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

Lixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum for $2.6M

2025-09-10T20:35:40.000Z - 9 months ago

Lixte Biotechnology purchases 10.5 Bitcoin, 300 Ethereum for $2.6M

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

Sep 10, 2025, 4:05 PM EDT - 9 months ago

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

Sep 5, 2025, 8:35 AM EDT - 9 months ago

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

Lixte Biotechnology appoints two new board members, Stazzone as CFO

2025-09-03T12:21:32.000Z - 9 months ago

Lixte Biotechnology appoints two new board members, Stazzone as CFO

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Sep 3, 2025, 8:00 AM EDT - 9 months ago

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

Aug 27, 2025, 8:15 AM EDT - 10 months ago

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Aug 25, 2025, 8:05 AM EDT - 10 months ago

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

Aug 19, 2025, 11:18 AM EDT - 10 months ago

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

Lixte Biotechnology provides update on recent corporate activities

2025-08-18T12:16:08.000Z - 10 months ago

Lixte Biotechnology provides update on recent corporate activities

LIXTE Biotechnology Holdings Provides Corporate Update

Aug 18, 2025, 8:00 AM EDT - 10 months ago

LIXTE Biotechnology Holdings Provides Corporate Update

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Aug 14, 2025, 9:06 PM EDT - 10 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

Aug 14, 2025, 8:05 AM EDT - 10 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

Aug 13, 2025, 8:49 AM EDT - 10 months ago

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

Lixte Biotechnology updates treasury policy to include cryptocurrency

2025-08-13T11:45:10.000Z - 10 months ago

Lixte Biotechnology updates treasury policy to include cryptocurrency

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

Aug 13, 2025, 7:30 AM EDT - 10 months ago

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

Lixte regains compliance with Nasdaq’s Continued Listing requirements

2025-07-16T12:10:21.000Z - 11 months ago

Lixte regains compliance with Nasdaq’s Continued Listing requirements

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Jul 16, 2025, 8:05 AM EDT - 11 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Jul 9, 2025, 5:15 PM EDT - 11 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Lixte Biotechnology announces publication in Nature journal on LB100 trials

2025-07-09T12:26:48.000Z - 11 months ago

Lixte Biotechnology announces publication in Nature journal on LB100 trials

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 9, 2025, 8:05 AM EDT - 11 months ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 8, 2025, 2:57 PM EDT - 11 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 2, 2025, 4:05 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology files to sell 467,393 shares of common stock for holders

2025-04-04T20:10:25.000Z - 1 year ago

Lixte Biotechnology files to sell 467,393 shares of common stock for holders

Lixte Biotechnology launches new study in collaboration with NKI on LB-100

2025-03-31T12:40:08.000Z - 1 year ago

Lixte Biotechnology launches new study in collaboration with NKI on LB-100

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 31, 2025, 8:30 AM EDT - 1 year ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Lixte Biotechnology provides update on progress with LB-100

2025-03-27T12:47:18.000Z - 1 year ago

Lixte Biotechnology provides update on progress with LB-100

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Mar 27, 2025, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Lixte announces online publication of new pre-clinical data in BioXriv

2025-03-10T12:40:43.000Z - 1 year ago

Lixte announces online publication of new pre-clinical data in BioXriv

Lixte Biotechnology adds Lurie Cancer Center as second site in LB-100 trial

2025-02-25T13:56:36.000Z - 1 year ago

Lixte Biotechnology adds Lurie Cancer Center as second site in LB-100 trial

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 25, 2025, 8:30 AM EST - 1 year ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Lixte Biotechnology announces closing of $1.05M registered direct offering

2025-02-13T15:43:44.000Z - 1 year ago

Lixte Biotechnology announces closing of $1.05M registered direct offering

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 10:35 AM EST - 1 year ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 1 year ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Feb 10, 2025, 5:00 PM EST - 1 year ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Sep 4, 2024, 8:30 AM EDT - 1 year ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 26, 2024, 8:30 AM EDT - 1 year ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 19, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 15, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 10:50 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 11:00 AM EDT - 2 years ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Jun 3, 2024, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 20, 2024, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

DARKP00L
DARKP00L Jun. 3 at 1:09 PM
$LIXT 08:38 on Jun. 03 2026 LIXTE Biotechnology Announces ~$16.57M Registered Direct Offering, Selling ~2.625M Shares And Pre-Funded Warrants At A Combined Price Of $6.31 #tradeideas
0 · Reply
topstockalerts
topstockalerts Jun. 2 at 1:15 AM
$LIXT the buyers seem to be operating with confidence.
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 2:01 PM
$LIXT 08:52 on Jun. 01 2026 LIXTE Biotechnology To Seek Strategic Acquisition Partner For Its Clinical Stage Pharmaceutical And Med-Tech Business #tradeideas
0 · Reply
Scoty_D
Scoty_D Jun. 1 at 1:47 PM
$LIXT The tape is looking funky. 1 share fight going back n forth, odd.
0 · Reply
rockitpicks
rockitpicks Jun. 1 at 1:25 PM
$LIXT There is more going on then what the headline reads..They always release a snippet of info before the full story. This might be building into a serious runner
0 · Reply
Paraboljoker
Paraboljoker Jun. 1 at 12:53 PM
$ADVB $LIXT bio watch lowfloats on 🤔
0 · Reply
TA_Kongen
TA_Kongen Jun. 1 at 12:52 PM
$LIXT LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors Years of biotech headlines all fluff. No real company pivots one day into AI after years of biotech work lmfao.
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 1 at 12:50 PM
$LIXT LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
0 · Reply
DavidScott
DavidScott Jun. 1 at 2:52 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $TROO $LIXT $TOON $NNDM $INO
0 · Reply
focafoca99
focafoca99 May. 14 at 9:28 PM
$LIXT citing its Q1 2026 10‑Q, reported progress on its LB‑100 trial and expansion of its Liora proton‑therapy subsidiary.
0 · Reply
DonutHole
DonutHole May. 8 at 5:09 PM
$LIXT added to the list. https://www.realcreativeagency.com/best-penny-stocks-to-watch/#LIXT
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 4:35 AM
$LIXT
0 · Reply
RETAlerts
RETAlerts May. 5 at 8:09 PM
Scanner caught the setup on $LIXT early. Clean consolidation before the move. +9.2% now shows why algo systems flag this pattern.
0 · Reply
topstockalerts
topstockalerts May. 5 at 8:08 PM
$LIXT this just keeps pushing without much effort
0 · Reply
KoalaFlipper
KoalaFlipper May. 5 at 4:05 PM
$LIXT check out $OTLK
0 · Reply
ReadyMate
ReadyMate May. 5 at 3:48 PM
$LIXT anyone here? Any idea what just happened?
1 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 24 at 7:07 PM
TinyGemsBreaks – $LIXT Unlocking New Potential in Precision Cancer Treatment https://ibn.fm/ro6jj
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 22 at 1:11 PM
$LIXT making a change to u
1 · Reply
Investor6
Investor6 Apr. 21 at 6:47 AM
$PMAX June 2025, Pursglove became CEO of Lixte ( $LIXT ) . LIXT went from $1.10 to $5.40 in three months.
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 17 at 5:52 PM
MissionIRNewsBreaks – $LIXT Positions LB-100 as Novel Approach in Cancer Treatment Landscape https://ibn.fm/yoogt
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 17 at 5:38 PM
MissionIRNewsBreaks – $LIXT Positions LB-100 as Novel Approach in Cancer Treatment Landscape https://ibn.fm/yoogt
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 15 at 4:51 PM
Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients $LIXT https://ibn.fm/WNIG7
0 · Reply